Northwest Biotherapeutics, Inc.
- Jurisdiction
United States - LEI
5493002DRWWEOWTT8005 - ISIN
US66737P6007 (NWBO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€933.13K - Gross margin
100.0% - EBIT
-€55.77M - EBIT margin
-5,977.1% - Net income
-€70.44M - Net margin
-7,548.7%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions